Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older women
Neil Carleton,Sanghoon Lee,Ruxuan Li,Jian Zou,Daniel D Brown,Jagmohan Hooda,Alexander Chang,Rahul Kumar,Linda R Klei,Lora H Rigatti,Joseph Newsome,Dixcy Jaba Sheeba John Mary,Jennifer M Atkinson,Raymond E West III,Thomas D Nolin,Patrick J Oberly,Ziyu Huang,Donald Poirier,Emilia J Diego,Peter C Lucas,George Tseng,Michael T Lotze,Priscilla F McAuliffe,Ioannis K Zervantonakis,Steffi Oesterreich,Adrian V Lee
DOI: https://doi.org/10.1101/2024.10.18.616978
2024-10-21
Abstract:Estrogen receptor positive (ER+) breast cancer is the most common subtype of breast cancer and is an age-related disease. The peak incidence of diagnosis occurs around age 70, even though these post-menopausal patients have low circulating levels of estradiol (E2). Despite the hormone sensitivity of age-related tumors, we have a limited understanding of the interplay between systemic and local hormones, chronic inflammation, and immune changes that contribute to the growth and development of these tumors. Here, we show that aged F344 rats treated with the dimethylbenz(a)anthracene / medroxyprogestrone acetate (DMBA/MPA) carcinogen develop more tumors at faster rates than their younger counterparts, suggesting that the aged environment promotes tumor initiation and impacts growth. Single-nuclei RNA-seq (snRNA-seq) of the tumors showed broad local immune dysfunction that was associated with circulating chronic inflammation. Across a broad cohort of specimens from patients with ER+ breast cancer and age-matched donors of normal breast tissue, we observe that even with an estrone (E1)-predominant estrogen disposition in the systemic circulation, tumors in older patients increase HSD17B7 expression to convert E1 to E2 in the tumor microenvironment (TME) and have local E2 levels similar to pre-menopausal patients. Concurrently, trackable increases in several chemokines, defined most notably by CCL2, promote a chronically inflamed but immune dysfunctional TME. This unique milieu in the aged TME, characterized by high local E2 and chemokine-enriched chronic inflammation, promotes both accumulation of tumor-associated macrophages (TAMs), which serve as signaling hubs, as well as polarization of TAMs towards a CD206+/PD-L1+, immunosuppressive phenotype. Pharmacologic targeting of estrogen signaling (either by HSD17B7 inhibition or with fulvestrant) and chemokine inflammation both decrease local E2 and prevent macrophage polarization. Overall, these findings suggest that chronic inflammation and hormonal disposition are critical contributors to the age-related nature of ER+ breast cancer development and growth and offer potential therapeutic insight to treat these patients.
Cancer Biology